IMVTHIGH SIGNALFINANCIAL10-K

IMVT experienced severe financial deterioration with net losses increasing 60% to $414M while burning through $376M in operating cash flow, indicating accelerating cash consumption despite increased equity funding.

The company is in a critical cash burn phase typical of late-stage biotech development, with R&D expenses surging 48% to $102M as clinical trials advance. While stockholders' equity increased 14.5% suggesting recent equity raises provided funding, the dramatic increase in operating losses and cash burn rate raises questions about runway duration and potential need for additional financing.

Comparing 2025-05-29 vs 2024-05-29View on EDGAR →
FINANCIAL ANALYSIS

IMVT's financials show a company in heavy investment mode with total assets growing 16.5% to $776M and stockholders' equity up 14.5% to $707M, indicating successful capital raising. However, operational metrics deteriorated sharply with net losses expanding 60% to $414M, R&D expenses jumping 48% to $102M, and operating cash outflows increasing 76% to $376M. The 17% increase in outstanding shares (from 146M to 171M) combined with stronger balance sheet suggests recent equity dilution funded operations, but the accelerating burn rate signals potential future financing needs.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+110.8%
$360K→$759K

Capital expenditure jumped 110.8% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
-75.5%
-$214.2M→-$375.9M

Operating cash flow fell 75.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
-61%
$5.3M→$2.1M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Net Income
P&L
-59.6%
-$259.3M→-$413.8M

Net income declined 59.6% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+48.4%
$68.6M→$101.8M

R&D investment increased 48.4% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
+41.5%
$48.6M→$68.8M

Liabilities grew 41.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+41.5%
$48.6M→$68.8M

Current liabilities surged 41.5% — significant near-term obligations; verify ability to meet short-term debt.

Total Assets
Balance Sheet
+16.5%
$666.4M→$776.2M

Asset base grew 16.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+15.3%
$665.8M→$767.7M

Current assets grew 15.3% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+14.5%
$617.8M→$707.4M

Equity base grew 14.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2025-05-29
PRIOR — 2024-05-29
ADDED
As of May 23, 2025, the registrant had 170,923,191 shares of common stock, $0.0001 par value per share, outstanding.
Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control and we may not be able to enroll patients in our trials on our anticipated timelines.
Our product candidates may be associated with adverse events or cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the commercial viability of any approved label or market acceptance.
Our business could be adversely affected by economic downturns, changes in inflation and interest rates, changes in international trade policies and tariffs, natural disasters, political crises, geopolitical events, such as the crises in Ukraine and the Middle East, or other macroeconomic conditions, which may in the future negatively impact our business and financial performance.
We do not have our own manufacturing capabilities and rely on third parties to produce clinical supplies and commercial supplies of our product candidates.
+7 more — sign up free →
REMOVED
As of May 22, 2024, the registrant had 146,053,941 shares of common stock, $0.0001 par value per share, outstanding.
Table of Content s SUMMARY RISK FACTORS You should consider carefully the risks described under Risk Factors in Part I, Item 1A of this Annual Report on Form 10-K.
Our product candidates, or anti-FcRn product candidates or products developed by others, may cause adverse events or undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the scope of any approved label or market acceptance.
Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.
Our business could be adversely affected by economic downturns, changes in inflation, increases in interest rates, natural disasters, political crises, geopolitical events, such as the crises in Ukraine and the Middle East, or other macroeconomic conditions, which may in the future negatively impact our business and financial performance.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →